Tenders Are Invited For Topotecan As Hydrochloride 4Mg Vial (Powder For Reconstitution Or 4Mg/4Ml Concentrated Solution), Etc

Tenders are invited for Topotecan as Hydrochloride 4mg Vial (Powder for Reconstitution or 4mg/4ml Concentrated Solution), Etc. "Topotecan (as hydrochloride) 4mg vial (powder for reconstitution or 4mg/4ml concentrated solution) 1297 Maintain the 2027 requirement levels at the same level as 2026 (no increase), in accordance with the recommendation of the relevant advisory committee for the following agents: Cetuximab, mirvetuximab, topotecan 1287 The requirement for Topotecan for the year 2027 shall be increased by 25%. 1276 1270 Indications: 1- 2nd-line treatment of small-cell lung cancer following failure of 1st-line chemotherapy (usually platinum + etoposide) 2- Ovarian cancer Metastatic ovarian cancer following failure of initial or subsequent chemotherapy 3- Cervical cancer Combination therapy with cisplatin for stage IVB recurrent or persistent cervical carcinoma that cannot be treated with surgery or radiation therapy 1263 The item is approved for inclusion in the Essential List for a patient population of 450, at an approximate cost of $500,000." Thyroxine sodium or anhydrous Levothyroxin Sodium 50mcg tablet Thyroxine sodium or anhydrous Levothyroxin Sodium 100mcg Tablet "Baclofen 500mcg/ml (20ml) or Baclofen 2mg/ml (5ml) ampoule for use with implantable pump intrathecal injection 1190 Reviewing equipment requirements to align with actual material needs and clinical indications, through a joint committee comprising the advisory committees for neurology, neurosurgery, and pediatrics. Closing date 13/10/2026 Tender Link : https://kimadia.gov.iq/en/category/medicines/